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Abstract 
Background: Malaria and HIV/AIDS constitute major public health problems in Ethiopia, but the burden associated 
with malaria-HIV co-infection has not been well documented. In this study, the burden of malaria among HIV posi-
tive and HIV negative adult outpatients attending health facilities in Oromia National Regional State, Ethiopia was 
investigated.
Methods: A comparative cross-sectional study among HIV-positive patients having routine follow-up visits at HIV 
care and treatment clinics and HIV-seronegative patients attending the general medical outpatient departments in 
12 health facilities during the peak malaria transmission season was conducted from September to November, 2011. 
A total of 3638 patients (1819 from each group) were enrolled in the study. Provider initiated testing and counseling 
of HIV was performed for 1831 medical outpatients out of whom 1819 were negative and enrolled into the study. 
Malaria blood microscopy and hemoglobin testing were performed for all 3638 patients. Data was analyzed using 
descriptive statistics, Chi square test and multivariate logistic regression.
Results: Of the 3638 patients enrolled in the study, malaria parasitaemia was detected in 156 (4.3 %); malaria para-
sitaemia prevalence was 0.7 % (13/1819) among HIV-seropositive patients and 7.9 % (143/1819) among HIV-seron-
egative patients. Among HIV-seropositive individuals 65.4 % slept under a mosquito bed net the night before data 
collection, compared to 59.4 % of HIV-seronegative individuals. A significantly higher proportion of HIV-seropositive 
malaria-negative patients were on co-trimoxazole (CTX) prophylaxis as compared to HIV-malaria co-infected patients: 
82 % (1481/1806) versus 46 % (6/13) (P = 0.001). HIV and malaria co-infected patients were less likely to have the 
classical symptoms of malaria (fever, chills and headache) compared to the HIV-seronegative and malaria positive 
counterparts. Multivariate logistic regression showed that HIV-seropositive patients who come for routine follow up 
were less likely to be infected by malaria (OR = 0.23, 95 % CI = 0.09–0.74).
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Background
Malaria and HIV are major global public health prob-
lems, with a particular impact in sub-Saharan Africa. 
Malaria and HIV share extensive epidemiological over-
lap, co-infecting large numbers of people in many Afri-
can countries. Indeed, it has been emphasized that any 
form of interaction between the two diseases will have a 
profound implication for treatment, care and prevention 
programs targeting both diseases [1].
Three-quarters of Ethiopia’s land mass is considered 
endemic for malaria, with most cases due to Plasmodium 
falciparum and Plasmodium vivax being the dominant 
species. Malaria transmission is seasonal and unstable, 
the peak transmission season being from September to 
December. In 2011 the Ethiopian Federal Ministry of 
Health (FMOH) reported that malaria accounted for up to 
17 % of outpatient consultations and 8 % of health facility 
admissions in the country; 3,898,319 cases were reported 
[2]. According to the Ethiopian Demographic and Health 
Survey (EDHS) 2011, the adult HIV prevalence was 1.5 % 
(1.9 % in women and 1 % in men), with prevalence being 
4.2 and 0.6 % in urban and rural areas, respectively [3].
Although malaria and HIV are major causes of morbid-
ity and mortality in the country, the burden of malaria-
HIV co-infection in Ethiopia is not well documented. 
A cross-sectional study conducted in the Hadiya zone, 
southern Ethiopia, found no difference in the prevalence of 
HIV among P. falciparum positive study participants and 
the general population [4]. Available evidence on the bio-
logical and operational interaction of malaria and HIV is 
scarce making it difficult to advocate for support in inte-
grated malaria/HIV programming. Additional informa-
tion is required to determine the burden of malaria among 
HIV positive persons in order to design appropriate strate-
gies for malaria prevention and control in this population 
group. The objective of this study was to determine –in an 
operational programme setting—the burden of malaria 
infection among HIV-positive and HIV-negative adult 
population groups in Oromia Regional State, Ethiopia.
Methods
Study setting
A cross-sectional study was conducted among (1) HIV-
negative patients visiting medical outpatient departments 
(OPD), and (2) HIV-positive patients attending HIV clin-
ics for routine follow-up at 12 health facilities in Oromia 
from September to November, 2011. Household and 
school malaria surveys conducted in Oromia reported a 
parasite prevalence ranging from 0.5 to 10.3 % [5, 6]; both 
P. falciparum and P. vivax are endemic in the study sites 
and the study was conducted during the peak malaria 
transmission season. HIV prevalence (adjusted for rural/
urban) in Oromia was 1.5–1.7  % according HIV senti-
nel surveillance in 2009 [7] and the EDHS 2011 [3]. Six 
hospitals (i.e. Limugenet, Shashemene, Metehara, Chiro, 
Gelemso, and Wonji) and six nearby health centres (i.e. 
Welenchiti, Shashemene, Metehara, Batu, Hirna, and 
Agaro) (Fig.  1) were selected for the study based on 
accessibility, patient load, availability of chronic HIV care 
and treatment services, and malaria endemicity within 
their respective catchment areas.
Sampling method, patient enrollment, clinical 
and laboratory analysis
Sample size was calculated to compare malaria preva-
lence in the two patient groups with differing HIV status. 
Malaria prevalence overall was estimated at 2.5 % based on 
administrative reports from similar settings, and malaria 
prevalence among HIV positive individuals was assumed 
to be 1.7 times the prevalence for HIV negative individuals 
[8]. Assuming a non-response rate of 2, 80 % power and 
5 % significance level, it was estimated that 1818 patients 
would have to be recruited in each study arm. This sam-
ple was proportionally distributed among the twelve study 
sites based on average quarterly HIV clinic patient load.
Study patients were enrolled from OPDs and the HIV 
clinics of health facilities. All visiting patients were 
assessed by health care providers for eligibility and 
enrollment using inclusion and exclusion criteria set for 
the study; written consent was obtained from all enrolled 
patients. Inclusion criteria were patients attending OPDs 
and HIV clinics, aged ≥18  years, residence in the sur-
rounding malarious villages, patients willing to give 
consent, patients with no mental illness or altered con-
sciousness, and—in the for OPD patients—willingness to 
undergo an HIV test. Patients identified at OPD as HIV-
positive were excluded from the study population and 
referred to HIV clinics for routine care (Figs. 2, 3).
Conclusion: The study documented lower malaria prevalence among the HIV-seropositive attendants who come 
for routine follow up. Clinical symptoms of malaria were more pronounced among HIV-seronegative than HIV-sero-
positive patients. This study also re-affirmed the importance of co-trimoxazole in preventing malaria symptoms and 
parasitaemia among HIV- positive patients.
Keywords: Comparative cross-sectional study, Ethiopia, Oromia, HIV, Malaria, Prevalence
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Consented patients were interviewed and examined by 
the study clinician. Physical examination was done for all 
patients including vital signs, weight and height measure-
ments, and examination of the conjunctiva for pallor. A 
single finger prick was performed by the laboratory tech-
nician and used to prepare one thick and one thin blood 
film. The slides were stained using 10 % Giemsa for ten 
minutes and air-dried before examination. Smears were 
labelled as negative after observing 100 fields at 1000 
magnification. When positive for malaria parasites, spe-
cies and parasite density against 200 leukocytes (assum-
ing an average leukocyte count of 8000 per µl) were 
determined. Each slide was re-read a second time by an 
experienced microscopist, blinded to initial microscopy 
result. A third blinded reading was conducted on all 
slides with discrepant in first and second slide readings: 
presence or absence of parasites or difference in species. 
The third reading was considered final.
HIV testing for patients seen at OPDs was conducted 
using the national algorithm, which includes three sero-
logical tests: KHB (KHB Shanghai Kehua Bio-engi-
neering Co. Ltd, China) as a screening test, STATPAK 
(Chembio Diagnostics System Inc., USA) as a confirma-
tory test, and—in case of discordance—UNIGOLD 
(Trinity Ciotech, USA) as a tie breaker. HemoCue Hb 301 
(HemoCue, Angelholm, Sweden) was used to determine 
the level of hemoglobin in all patients.
Data management and statistical analysis
A paper data collection instrument was developed, 
piloted and modified before use in the study. The instru-
ment had three parts: (a) general information about the 
participants including socio-demographic variables and 
use of long-lasting insecticidal nets (LLINs); (b) clinical 
information (e.g. list of anti-malarial drugs used 28 days 
prior to data collection), laboratory data (e.g. level of 
haemoglobin, blood film result, parasite species and den-
sity) and the treatment given to the patient for a specific 
problem identified on the same date of diagnosis; and 
(c) detail of the medications taken by the HIV-positive 
patients and their CD4 count results.
Data was double entered using SPSS Statistics 17.0 
(SPSS Inc., Chicago, USA). Any discrepancy between 
the two data sets was corrected by referring to the origi-
nal paper form. The final single data set was cleaned and 
analyzed using STATA 11.0 (Statacorp, College Station, 
USA) and SPSS Statistics 17.0 (SPSS Inc., Chicago, USA). 
Data were organized and summarized using descriptive 
Fig. 1 Location of study sites in Oromia National Regional state, Ethiopia
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statistics, Chi square tests, and multivariate logistic 
regression; P values of <0.05 were considered statistically 
significant.
Ethical considerations
Administrative clearance was obtained from all selected 
study sites and the Oromia Regional Health Bureau. 
Ethical clearance was obtained from the Institutional 
Review Boards of Columbia University (ethics number: 
AAAI2602) and the Ethiopian Public Health Association 
(ethics number: IORG0004760). All study participants 
were informed about the objective of the study and writ-
ten consent was obtained before patient enrollment.
Results
Socio‑demographic characteristics
A total of 3638 patients were enrolled into the study: half 
were HIV-negative and half were HIV-positive; equal 
numbers of HIV-positive and HIV-negative patients were 
enrolled from most of the facilities. The socio-demo-
graphics of the study population are given in Table  1: 
of study participants, 2006 (55.2  %) were female, 2131 
(58.7 %) were married, 748 (20.6 %) were daily laborers, 
and 2179 (59.9  %) had an income of ≤$30 per month; 
median age was 33 years (range: 18–99). The income of 
the poorest quintile accounted for 1 % while it is 55 % for 
the richest quintile. Malaria prevalence was 6.9 % in the 
3,515 consecutive patient 
visited to OPD 
3,515 Patients evaluated for 
their primary concern 
3,515 patients assessed for 
eligibility 
1,645 ineligible 1.870 found Eligible 
and requested for 
39 declined to 
give consent 
1.696 not enrolled to the 
study 1,831 provided informed 
consent for enrollment and 
HIV testing 
1,819 tested HIV 
negative 12 tested HIV 
positive 
1,819 enrolled to 
the study 
Fig. 2 Enrollment of study participants at OPD
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poorest versus 3.3 % in the richest quintile. The propor-
tion of malaria parasitaemia positive patients was higher 
in the poorest than the richest quintiles (32 vs 15  %, 
P = 0.18) and proportion of mosquito net availability is 
lower in the poorest than the richest quintile (15 vs 24 %, 
P < 0.0001).
Clinical and parasitological findings
Out of the total study participants 156 (4.3  %) had 
malaria parasitaemia, with P. falciparum and P. vivax 
representing 48.1 and 51.9  % of infections respectively. 
The median of the parasite density was 3060 parasites/µL 
(range 128–91,555). In 60.9 % of the parasitaemic slides, 
the parasite load was below 5000 parasites/µL (Table 2).
Of the study patients, 1473 (920 HIV negative and 553 
HIV positive) had reported subjective fever. Taking a 
temperature of 37.5 °C as a cut-off point for febrile status, 
15.5 % (283/1816) of the HIV negative patients and 8 % 
(148/1813) of the HIV positive patients were febrile.
The mean haemoglobin value for the 156 malaria posi-
tive patients was 13.93 mg/dl, while it was 14.06 for the 
rest. Again, the mean hemoglobin value of the 283 OPD 
malaria febrile patients was 14.2, it was 14.56 for the 
remaining individuals. Moreover, mean haemoglobin 
for HIV malaria co-infected was 12.72, where as for HIV 
mono-infected individuals it was 13.62 mg/dl.
Malaria parasitaemia prevalence was 7.9 % (143/1819) 
in HIV-negative patients. The geometric mean of the 
parasite count in this group was 2933 (95  % CI 2371–
3626), where as parasitaemia prevalence was 0.7  % 
(13/1819) in the HIV-positive patients. The geometric 
mean of the parasite count in this group was 4931 (95 % 
CI 2028–12,004). The parasite load in 53/143 (37.1 %) of 
the malaria parasite positive samples from HIV-negative 
patients was >5000 parasites/µL, however, parasite load 
in 8/13 (61.5 %) of the HIV-positive patients was >5000 
parasites/µL.
The majority of the HIV-positive patients 1419 (78 %) 
were on antiretroviral treatment (ART), 52.3  % of them 
for less than 2  years. Being on ART was not associated 
with protection from malaria infection among HIV posi-
tive individuals. Similarly, 1473 (81  %) of them were on 
co-trimoxazole prophylactic therapy (CPT), 54 % of them 
for less than 2 years. A significant difference in CPT use 
was noted among malaria parasitaemia positive (6/13, 
46  %) and malaria parasitaemia negative 1481/1806, 
3,251 consecutive HIV 
sero-positive patients 
visited the HIV clinic 
3,251 patients evaluated for 
his/her primary concern 
3,251 patients assessed for 
eligibility 
1,411 found ineligible 
1,840 found eligible and 
requested for consent 
1,432 not enrolled 
to the study 
21 declined to give 
consent 
1,819 provided informed 
consent 
1,819 enrolled to the study 
Fig. 3 Enrollment of study participants at HIV clinic
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(82  %) HIV positive patients (P  =  0.001) as shown in 
Table 3.
Malaria patients
HIV-positive, malaria co-infected patients were 
less likely to have fever [OR  =  0.24 (95  % CI 0.06–
0.95), P  =  0.04] or a headache [OR  =  0.15 (95  % CI 
0.04–0.61)]; HIV-positive patients had lower mean 
hemoglobin levels [mean difference  =  1.32 (95  % CI 
0.2–2.45), P = 0.02] compared to HIV-negative malaria-
infected patients (Table 4). Overall, there was no signifi-
cant difference between the parasite densities between 
the two patient groups, including when adjusted by 
fever status (Fig. 4).
Table 1 Socio-demographic characteristics of study participants
Socio‑demographic variables No. of HIV negative n (%) No. of HIV positive n (%) Total n (%)
Age (in years)
 ≤20 303 (16.7) 49 (2.7) 352 (9.7)
 21–30 642 (35.3) 664 (36.5) 1306 (35.9)
 31-40 391 (21.5) 658 (36.2) 1049 (28.8)
 41–50 277 (15.2) 292 (16.5) 569 (15.6)
 51–60 141 (7.8) 108 (5.9) 249 (6.8)
 61–70 41 (2.3) 39 (2.1) 80 (2.2)
 ≥71 24 (1.3) 9 (0.5) 33 (0.9)
Sex
 Male 974 (53.6) 657 (36.1) 1631 (44.8)
 Female 845 (46.5) 1161 (63.9) 2006 (55.2)
Occupation
 Farmer 491 (27.0) 195 (10.7) 686 (18.9)
 Business 85 (4.7) 193 (10.6) 278 (7.6)
 Student 213 (11.7) 22 (1.2) 235 (6.5)
 Civil servant 406 (22.3) 180 (9.9) 586 (16.1)
 Daily laborer 146 (8.0) 602 (33.1) 748 (20.6)
 Others 478 (26.3) 626 (34.4) 1104 (30.4)
Marital status
 Married 1218 (67.1) 913 (50.3) 2131 (58.7)
 Single 446 (24.6) 176 (9.7) 622 (17.1)
 Divorced 56 (3.1) 322 (17.7) 378 (10.4)
 Widowed 94 (5.2) 406 (22.3) 500 (13.8)
Income (US $ per month)
 ≤30 839 (46.1) 1340 (73.8) 2179 (59.9)
 >30 980 (53.9) 479 (26.33) 1459 (40.1)
Table 2 Malaria species and parasite density among study participants
Category HIV negative (%) (n = 143) HIV positive (%) (n = 13) Total (%) (n = 156)
Malaria parasite species
 P. falciparum 69 (48.3) 6 (46.2) 75 (48.1)
 P. vivax 74 (51.8) 7 (53.9) 81 (51.9)
Parasite density
 ≤5000 90 (62.9) 5 (38.5) 95 (60.9)
 5001–10,000 24 (16.8) 6 (46.2) 30 (19.2)
 10,001–15,000 16 (11.2) 0 (0.0) 16 (10.3)
 15,001–20,000 6 (4.2) 0 (0.0) 6 (3.9)
 ≥20,001 7 (4.9) 2 (15.4) 9 (5.8)
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Risk factors
Among all the study participants, 2155 (59.2 %) reported 
that they owned LLINs, and ownership was higher in 
the HIV-negative group than the HIV positive study 
group 1167 (64 %) vs 988 (54 %), χ2 = 36.47, P < 0.0001. 
Of the patients who reported LLINs ownership, 1335 
(62  %) reported that they had slept under it the night 
before the survey, 65.4 % in the HIV-positive and 59.4 % 
in the HIV-negative individuals (P =  0.004). There was 
no significant difference in LLIN use between malaria-
HIV co-infected and HIV infected patients (31 vs 35 %, 
P  =  0.73). Potential confounders including age, sex, 
occupation, income, family size, ownership and use of an 
LLIN, use of anti-malarial drugs, [i.e. ACT (Coartem®), 
chloroquine, doxycycline, sulfadoxine-pyrimethamine, 
quinine], ART and CPT were assessed. The crude odds 
ratio (OR) for the association between malaria parasitae-
mia and patient’s HIV status was 0.08 (95 % CI = 0.04–
0.14). Difference of the adjusted OR was considered if 
the crude OR was found beyond ±20 %. Only two varia-
bles (CPT and ART) were labelled as confounders. Based 
on the set criteria, the crude and adjusted ORs for the 
two variables (CPT and ART) differed. The crude and 
adjusted ORs including CPT and ART were 0.08 (95  % 
CI = 0.04–0.14) and 0.25 (95 % CI = 0.11–0.53), respec-
tively. Finally, a multivariate logistic regression analysis 
including the confounders in the model resulted in an 
Table 3 Characteristics of  HIV positive malaria co-infected patients compared to  HIV positive patients without  malaria 
infection
IQR inter-quartile range
Patient characteristics Blood film positive (n = 13) Blood film negative (n = 1806) P value
Percent male 46 % 36 % 0.45
Mean age 37.76 36.01 0.54
% With mosquito net at home 54 % 54 % 0.98
% Use of mosquito net 31 % 35 % 0.73
% On CPT 46 % 82 % 0.001
% On ART 69 % 78 % 0.44
Median (IQR) cd4 count (cells/mm3) 493 (297–551) 356 (231–524) 0.08
Mean haemoglobin level 12.72 13.62 0.10
Table 4 Clinical characteristics of blood film positive study participants
Patient characteristics Malaria positive P value
HIV negative (n = 143) HIV positive (n = 13)
% With reported fever 83 % 54 % 0.04
% With chills 78 % 54 % 0.14
% With headache 88 % 54 % 0.002
Mean temperature (°C) 36.8 36.4 0.24
Febrile (≥37.5 °C) 41.5 % 23.1 % 0.19
Systolic blood pressure (mmHg) 106.6 106.9 0.95
Diastolic blood pressure (mmHg) 72.1 74.6 0.45
Mean haemoglobin level (gm/dl) 14.0 12.7 0.02
Fig. 4 Box and whisker plots of log10 parasite densities (parasites × 
103/µL) comparing HIV negative and HIV positive patients by afebrile 
and febrile strata. Boxes represent the interquartile range, whiskers are 
a maximum of 1.5 times the interquartile range, outliers are shown as 
circles and stars
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OR of 0.23 (95 % CI = 0.09–0.74) as shown in Tables 5 
and 6.
Discussion
Until 1998, there was “no convincing evidence for an 
interaction between malaria and HIV” [9]. Accumulated 
evidences revealed that HIV positive people in areas of 
malaria transmission have more frequent episodes of 
symptomatic malaria and higher parasitaemia than those 
without HIV [10, 11]. By 2006, it was estimated that the 
interaction of malaria and HIV in one Kenyan district 
alone had caused 980,000 excess malaria episodes and 
8500 excess HIV infections since HIV’s emergence in the 
1980s [12]. Malaria is more common and severe in adults 
with HIV, pregnant women, and children. The study 
on interaction of malaria and HIV in Africa has shown 
that HIV viral load is greater in women with placental 
malaria, and infants born to women with both HIV and 
placental malaria are of greater risk of premature deliv-
ery, low birth weight, or death compared with infants 
born to women with HIV infection alone. The study also 
showed malaria causes increased HIV viral load in blood 
and breast milk and reduced CD4 cell count [13]. Malaria 
treatment is less effective in non-pregnant adults with 
HIV [14].
The current study demonstrated that—in an opera-
tional setting with scaled-up HIV/AIDS services and 
a setting of seasonal malaria transmission—HIV-pos-
itive patients attending HIV specialty clinics were less 
likely to have malaria parasitaemia compared to HIV-
negative patients attending general OPD clinics dur-
ing peak malaria transmission season (OR =  0.23; 95 % 
CI  =  0.09–0.74). In this study, the malaria prevalence 
in HIV-positive patients was similar (i.e. 0.7  %) to the 
0.5 % prevalence among the general population in Oro-
mia as reported from the national Malaria Indicator Sur-
vey (MIS) 2011 [6] conducted in the same transmission 
season. The MIS survey was a cross-sectional study that 
screened the population within households for malaria 
parasitaemia regardless of whether or not there were any 
acute malaria illness symptoms. In this study, many gen-
eral medical outpatient department patients were self-
selected due to the presence of acute symptoms of illness 
that required immediate relief, whereas the HIV positive 
patients attending HIV specialty clinic were more likely 
to be receiving routine medical care follow-up and health 
maintenance including medication refills.
In a prospective study conducted in 196 patients using 
rapid antigen diagnostic tests in Nigeria, the prevalence 
rate of P. falciparum malaria among HIV sero-negative 
group was 10.6  % and amongst HIV sero-positives was 
Table 5 Patient characteristics associated in  univariate 
analysis with  blood film result among  the study partici-
pants
Variables OR 95 % CI
Age
 ≤20 1 Reference
 21–30 0.33 0.22–0.50
 31–40 0.19 0.11–0–31
 41–50 0.21 0.12–0.39
 51–60 0.34 0.17–0.68
 61–70 0.19 0.04–0.81
 ≥71 0.74 0.21–2.52
Sex
 Male 1 Reference
 Female 0.45 0.32–0.63
Occupation
 Farmer 1 Reference
 Business 0.2 0.07–0.57
 Student 1.96 1.20–3.21
 Civil servant 0.52 0.30–0.88
 Daily labourer 0.34 0.20–0–60
 Others 0.49 0.32–0.77
Income
 ≤$30.00/month 1 Reference
 >$30.00/month 1.07 0.77–1.48
Family size
 1–5 1 Reference
 6–10 1.25 0.88–1.78
 11+ 0.71 0.17–2.94
TMP/SMX
 No 1 Reference
 Yes 0.05 0.02–0.12
Sleep under net
 No 1 Reference
 Yes 0.67 0.5–0.95
Sulfadoxine-pyrimethamine
 No 1 Reference
 Yes 0.00 –
Quinine
 No 1 Reference
 Yes 0.00 –
Coartem
 No 1 Reference
 Yes 4.90 2.24–10.71
Chloroquine
 No 1 Reference
 Yes 4.04 1.78–9.19
Doxycycline
 No 1 Reference
 Yes 0.77 0.10–5.68
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18.9 % [15]. In addition, studies conducted elsewhere in 
higher malaria transmission settings strongly suggested 
increased risk of malaria in HIV infected individuals 
[10, 11, 16–18]. According to results on malaria HIV co-
infection in eastern sub-Saharan Africa, individuals who 
lived in areas with high P. falciparum parasite rate have 
about twice the risk of being HIV positive compared 
with individuals who live in areas with low P. falciparum 
parasite rate [19]. In this study, both P. falciparum and P. 
vivax parasites were identified with similar distribution 
and parasite densities among malaria HIV co-infected 
and malaria mono-infected patients.
Although, a higher mean parasite density was observed 
in the febrile as compared to non-febrile patients and 
among HIV-positive and HIV-negative patients, no sta-
tistically significant difference was observed. Although 
there is a paucity of comparable evidence from the same 
setting, a study conducted by Cheryl et  al. in South 
Africa demonstrated no significant difference in para-
site count in HIV negative and positive individuals [20]. 
However, Tatfang et al. reported a significant difference 
in mean parasite count between the two patient groups 
[21].
This study also showed that HIV and malaria co-
infected patients were less likely to have the classical 
symptoms of malaria (fever, chills and headache) com-
pared to the HIV negative—malaria positive patients. 
Immunological reasons may have contributed for this 
finding. HIV patients’ lesser ability to manifest with the 
typical symptoms of malaria, which heralds a high index 
of suspicion could have a profound implication in clinical 
diagnosis. In contrast to the findings of this study, many 
studies conducted in malaria endemic regions indicated 
an increased risk of clinical malaria in HIV infected indi-
viduals consistent with the level of immune-suppression 
[11, 18, 22, 23]. This study has noted that the mean hemo-
globin level of HIV-malaria co-infected patients was 
also significantly lower than the malaria mono-infected 
patients (12.7 vs 14.0 g/dl, P = 0.02). This is similar with 
the results of a study conducted by Nkuo-Akenji et  al. 
that showed more prevalent anaemia in the malaria-HIV 
co-infected than in cases mono-infected with either HIV 
or malaria [24].
Some of the socio-demographic factors that included 
age, sex, occupation, marital status, and income were 
not found to be contributing to the difference observed 
in malaria prevalence among HIV-negative and positive 
study groups. Though not statistically significant, the 
proportion of malaria positive patients was higher in the 
poorest quintiles of the study participants compared to 
the richest, while the mosquito net availability was sig-
nificantly lower in the poorest than the richest quintile. 
Studies conducted so far have suggested that malaria 
should be regarded as a disease of the poor or a disease of 
poverty as it was always noted that the concentration of 
the disease was in poorest continents and countries [25]. 
Nevertheless, in a Malaria Indicator Survey conducted in 
Ethiopia in 2007, a 0.6 % of malaria prevalence was found 
in the poorest quintile as compared to 1.6 % in the richest 
quintile [26].
The HIV-positive patients compared to the HIV-neg-
ative patients were observed to have frequently slept 
under the mosquito net (P  =  0.004). The utilization of 
mosquito nets among the HIV positive study participants 
was not found to be protective for malaria infection. This 
result seems to be different from reports by other studies 
conducted elsewhere which could be due to the fact that 
this study might have been limited by the small number 
of malaria positives encountered among the HIV positive 
study participants. Although sleeping under mosquito 
nets was not significantly different among malaria-HIV 
co-infected and HIV mono-infected patients, the pro-
vision of CPT to the HIV positive patients have signifi-
cantly prevented infection from malaria. This concurs 
with the findings of a prospective cohort study conducted 
in Uganda which showed that the provision of CPT, ART, 
Table 5 continued
Variables OR 95 % CI
ART
 No 1 Reference
 Yes 0.09 0.04–0.18
TMP/SMX trimethoprim/sulfamethoxazole, ART anti-retroviral therapy
Table 6 Potential confounders which may distort the 
association between  malaria parasitaemia and  HIV status 
of patients






Family size 0.08 0.05–0.15
TMP/SMX 0.25 0.11–0.53
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and bed nets was associated with a 95 % fall in the fre-
quency of malaria from 50.8 to 2.1 episodes per 100 per-
son-years in HIV positive adults. The addition of ART to 
a cohort of HIV positive people already receiving CPT 
was associated with a 64 % fall in malaria incidence [27].
The presence of sub microscopic infections in low 
endemic settings like Ethiopia is increasingly getting 
attention. The study in Ethiopia on sub-microscopic car-
riage of P. falciparum and P. vivax in low endemic areas 
showed that malaria infections were not detected by 
microscopy despite >5 % parasite prevalence detected by 
nested poymerase chain reaction (nPCR). In this study all 
participants were malaria negative for microscopy and 
RDT. Nested PCR revealed P. falciparum mono-infec-
tion in 5.2 % (29/555), P. vivax mono-infection in 4.3 % 
(24/555), where as mixed infection was 0.2  % (1/555) 
[28] . Similarly, in the current study no mixed infection 
was observed and microscopy was used which is usu-
ally insensitive for low-density parasitaemia. Molecular 
techniques, on the other hand, allow the detection of 
low-level, sub-microscopy parasitaemia. Another study 
in Ethiopia has similarly showed that the prevalence 
of sub-microscopic P. falciparum carriage was 19.2  % 
(77/400) out of RDT and microscopy negative blood sam-
ples, while microscopy based prevalence of P. falciparum 
infection was 3.7 % (54/1453) [29].
This study has some limitations. Due to small number 
of HIV malaria co-infected individuals (n = 13) caution 
should be exercised in interpretation and further analy-
sis. The HIV-negative study participants were visiting 
health facilities at OPD to seek medical attention on self-
reported acute symptomatic illnesses, while the HIV pos-
itive patients came to the HIV clinic for a routine medical 
follow up. The differences in the malaria prevalence and 
clinical presentations in both study groups could, to 
some degree, be attributed to the inherent differences of 
the reasons for clinic attendance between the two study 
populations.
Conclusion
This study was conducted in an operational setting with 
scaled-up HIV/AIDS services and seasonal malaria trans-
mission. This study showed lower malaria prevalence in 
HIV-positive than HIV-negative patients. The prevalence 
of malaria in the HIV-positive population was similar 
to the general population’s malaria prevalence that was 
measured in the national MIS 2011. Use of insecticide-
treated mosquito nets was reportedly greater in the HIV-
positive than the HIV-negative study groups. This study 
reinforces the importance of CPT in preventing malaria 
among HIV positive patients.
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